Re-expressing the PD-L1 through DNA hypomethylating agent azacytidine (AZA) could sensitize the NSCLC cells to anti–PD-1 therapy in vitro and in vivo in a xenografted lung tumor model. The gene discussed is CD274; the disease is non-small cell lung carcinoma.